• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IDEXX Labs upgraded by Goldman with a new price target

    7/21/22 7:39:19 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email
    Goldman upgraded IDEXX Labs from Neutral to Buy and set a new price target of $435.00 from $530.00 previously
    Get the next $IDXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    1/30/2024$525.00Overweight → Neutral
    Piper Sandler
    12/7/2023$602.00Outperform
    Exane BNP Paribas
    12/4/2023Neutral → Buy
    Cleveland Research
    8/2/2023$610.00Overweight → Neutral
    Atlantic Equities
    7/25/2022$415.00Buy → Hold
    Stifel
    7/21/2022$530.00 → $435.00Neutral → Buy
    Goldman
    More analyst ratings

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Johnson Michael Perkins covered exercise/tax liability with 1,499 shares and converted options into 3,382 shares, increasing direct ownership by 390% to 2,365 units (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      6/3/25 5:00:38 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Szostak M Anne exercised 1,046 shares at a strike of $160.28 and sold $1,182,917 worth of shares (2,306 units at $512.97) (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/23/25 5:00:20 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Junius Daniel M exercised 2,683 shares at a strike of $263.81 and sold $1,358,697 worth of shares (2,683 units at $506.41) (SEC Form 4)

      4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

      5/14/25 5:00:15 PM ET
      $IDXX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care